Published in PLoS One on August 19, 2013
GAS5 long non-coding RNA in malignant pleural mesothelioma. Mol Cancer (2014) 0.97
KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma. Mol Cancer (2016) 0.86
Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot? Oncotarget (2017) 0.75
Diagnosis and prognosis-review of biomarkers for mesothelioma. Ann Transl Med (2017) 0.75
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc (2009) 137.99
A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res (2001) 124.61
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature (2010) 23.55
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature (2010) 13.82
Molecular mechanisms of long noncoding RNAs. Mol Cell (2011) 11.44
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol (2003) 11.22
A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell (2011) 10.50
The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell (2010) 8.66
MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene (2003) 7.90
Long noncoding RNAs in mouse embryonic stem cell pluripotency and differentiation. Genome Res (2008) 6.43
Analysis of gene expression data using BRB-ArrayTools. Cancer Inform (2007) 6.09
An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. Mol Cell (2009) 6.08
Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res (2011) 6.02
An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell (2011) 5.75
The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol (2012) 5.60
Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology (2006) 4.70
Altered nuclear retention of mRNAs containing inverted repeats in human embryonic stem cells: functional role of a nuclear noncoding RNA. Mol Cell (2009) 4.54
Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol (2011) 3.88
Complex Loci in human and mouse genomes. PLoS Genet (2006) 3.74
microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene (2011) 3.02
Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer (2004) 2.85
The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol (2011) 2.79
MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes. FEBS Lett (2010) 2.67
The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer Res (2011) 2.52
After Helsinki: a multidisciplinary review of the relationship between asbestos exposure and lung cancer, with emphasis on studies published during 1997-2004. Pathology (2004) 2.26
Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Mol Cell (2009) 2.05
Long intergenic noncoding RNA HOTAIR is overexpressed and regulates PTEN methylation in laryngeal squamous cell carcinoma. Am J Pathol (2012) 1.91
Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg (1994) 1.89
Long non-coding RNA HOTAIR is an independent prognostic marker for nasopharyngeal carcinoma progression and survival. Cancer Sci (2013) 1.88
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol (2007) 1.85
Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol (2005) 1.60
PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol (2010) 1.57
Occupational exposure to asbestos and ovarian cancer: a meta-analysis. Environ Health Perspect (2011) 1.51
The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. Urol Oncol (2012) 1.33
Detection of long non-coding RNA in archival tissue: correlation with polycomb protein expression in primary and metastatic breast carcinoma. PLoS One (2012) 1.33
Induction of drug resistance and transformation in human cancer cells by the noncoding RNA CUDR. RNA (2007) 1.24
mTOR signaling regulates the processing of pre-rRNA in human cells. Nucleic Acids Res (2011) 1.05
Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target. PLoS One (2009) 1.05
Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer (2006) 1.03
Clinical utility of prostate carcinoma molecular diagnostic tests. Rev Urol (2008) 0.93
Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair. Mol Cancer Ther (2013) 0.92
Transcriptional profiling of mesothelioma using microarrays. Lung Cancer (2005) 0.91
Phenotypes and karyotypes of human malignant mesothelioma cell lines. PLoS One (2013) 0.90
Molecular characterization of tumour heterogeneity and malignant mesothelioma cell differentiation by gene profiling. J Pathol (2005) 0.90
Immunoexpression of PAX 8 in endometrial cancer: relation to high-grade carcinoma and p53. Int J Gynecol Pathol (2011) 0.89
Validation of tissue microarray technology in malignant pleural mesothelioma. Pathology (2011) 0.86
Stabilization of human interferon-α1 mRNA by its antisense RNA. Cell Mol Life Sci (2012) 0.84
Gene expression profiling of malignant mesothelioma cell lines: cDNA array study. Int J Cancer (2001) 0.84
In vitro and in vivo characterization of highly purified human mesothelioma derived cells. BMC Cancer (2010) 0.82
Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells. Br J Cancer (2012) 0.82
Epigenomic targets for the treatment of respiratory disease. Expert Opin Ther Targets (2009) 0.81
Diagnosis of epithelial mesothelioma using tree-based regression analysis and a minimal panel of antibodies. Pathology (2009) 0.76
Thoracic metastasis in advanced ovarian cancer: comparison between computed tomography and video-assisted thoracic surgery. J Gynecol Oncol (2011) 0.76
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol (2011) 5.06
Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst (2007) 4.40
Haemolysis during sample preparation alters microRNA content of plasma. PLoS One (2011) 2.92
Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol (2010) 2.80
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther (2002) 2.60
Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol (2013) 2.55
High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res (2010) 2.50
Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology (2013) 2.32
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol (2013) 2.25
Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol (2005) 2.22
Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. J Thorac Oncol (2015) 2.17
Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol (2009) 2.06
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol (2010) 2.05
An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res (2009) 2.03
Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. Nat Genet (2002) 2.00
A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years' Experience. J Thorac Oncol (2015) 1.99
Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol (2003) 1.92
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol (2005) 1.89
Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol (2005) 1.87
Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. J Biol Chem (2003) 1.63
Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J (2003) 1.57
The Impact of Hemolysis on Cell-Free microRNA Biomarkers. Front Genet (2013) 1.54
Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer (2011) 1.53
Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem (2004) 1.46
Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One (2013) 1.45
Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol (2008) 1.43
Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer (2006) 1.43
Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene (2003) 1.42
Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol (2013) 1.38
Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer (2004) 1.37
Is there a need for expert opinion for biopsy diagnosis of difficult cases of malignant mesothelioma? Pathology (2012) 1.37
Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol (2011) 1.35
Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol (2010) 1.32
Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer. Clin Cancer Res (2005) 1.30
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis (2013) 1.27
NF-kappaB regulation: the nuclear response. J Cell Mol Med (2009) 1.27
The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol (2010) 1.22
Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. Clin Lung Cancer (2012) 1.22
Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol (2006) 1.21
Molecular and clinical spectrum of type I plasminogen deficiency: A series of 50 patients. Blood (2006) 1.20
Pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: metastasis or second primary? Clin Cancer Res (2005) 1.17
In vivo imaging of apoptosis by 99mTc-Annexin V scintigraphy: visual analysis in relation to treatment response. Radiother Oncol (2004) 1.17
Association of TCF4 and CLU polymorphisms with Fuchs' endothelial dystrophy and implication of CLU and TGFBI proteins in the disease process. Eur J Hum Genet (2012) 1.17
The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma. Ann Thorac Surg (2004) 1.16
Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One (2008) 1.14
Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. J Thorac Oncol (2008) 1.14
Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables. Lung Cancer (2002) 1.13
The MARS feasibility trial: conclusions not supported by data. Lancet Oncol (2011) 1.13
Cyclooxygenase-2-linked attenuation of hypoxia-induced pulmonary hypertension and intravascular thrombosis. J Pharmacol Exp Ther (2008) 1.12
Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer. J Clin Oncol (2007) 1.10
Does miR-1 play a role in malignant pleural mesothelioma development and progression? Chest (2013) 1.09
Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Ann Surg (2009) 1.09
Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int J Cancer (2011) 1.07
The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction. FASEB J (2007) 1.07
Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem (2003) 1.07
Protein kinase C activation downregulates human organic anion transporter 1-mediated transport through carrier internalization. J Am Soc Nephrol (2003) 1.06
Identification of LOXL1 protein and Apolipoprotein E as components of surgically isolated pseudoexfoliation material by direct mass spectrometry. Exp Eye Res (2009) 1.05
YB-1, the E2F pathway, and regulation of tumor cell growth. J Natl Cancer Inst (2011) 1.04
Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA. Mol Genet Metab (2007) 1.04
Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy. J Cell Mol Med (2009) 1.03
Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study. Lung Cancer (2011) 1.02
A rapid and sensitive method to detect siRNA-mediated mRNA cleavage in vivo using 5' RACE and a molecular beacon probe. Nucleic Acids Res (2009) 1.02
Therapeutic and biological importance of getting nucleotides out of cells: a case for the ABC transporters, MRP4 and 5. Adv Drug Deliv Rev (2002) 1.01
Receptor tyrosine kinases and their activation in melanoma. Pigment Cell Melanoma Res (2011) 1.01
Ipilimumab-induced immune-related renal failure--a case report. Anticancer Res (2012) 1.00
Epigenetics underpinning the regulation of the CXC (ELR+) chemokines in non-small cell lung cancer. PLoS One (2011) 0.99
Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer. J Thorac Oncol (2014) 0.99
Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. Eur J Cancer (2011) 0.98
PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer. J Pathol (2011) 0.97
Targeting oxidative stress in cancer. Expert Opin Ther Targets (2010) 0.97
Malignant pleural mesothelioma--an update. Int J Occup Environ Health (2004) 0.97
Novel quantitative trait loci for central corneal thickness identified by candidate gene analysis of osteogenesis imperfecta genes. Hum Genet (2009) 0.97
Cell-free microRNAs: potential biomarkers in need of standardized reporting. Front Genet (2013) 0.97
Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest (2002) 0.96
Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression. PLoS One (2012) 0.95
Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. Support Care Cancer (2012) 0.95
Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer (2004) 0.94
Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol (2012) 0.94
The ticking time-bomb of asbestos: its insidious role in the development of malignant mesothelioma. Crit Rev Oncol Hematol (2012) 0.93
Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair. Mol Cancer Ther (2013) 0.92
Promoter hypermethylation mediates downregulation of thiamine receptor SLC19A3 in gastric cancer. Tumour Biol (2009) 0.92